Boston Scientific Corporation (BSX)
Health Care7 articles
Price chart
Why is BSX moving today?
+0.6%BSX is +0.6% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 2 days ago
Boston Scientific Corporation (BSX) overview
Boston Scientific makes medical devices for cardiology and other specialties.
BSX is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Boston Scientific Corporation trades on the NYSE under the ticker symbol BSX. The most recent market data puts the share price at about $44.39. That is up 0.57% on the session. At that price the company is worth roughly $64.33B.
Over the past 52 weeks, BSX has traded between $41.39 and $105.65. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 18.0. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns.
Key statistics
Source: Yahoo Finance - quote as of 2 days ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BSX
BSX is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each BSX story as it breaks, and tags it bullish, bearish or neutral.
What moves BSX
- Earnings. BSX reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from BSX.
- Sector news. Health Care stocks often move together, so a rival's news can move BSX too.
Market Mood
Latest BSX news
Boston Scientific (BSX) Guidance Cut Due to Cyberattack Impact
Boston Scientific Corporation (NYSE: BSX) experienced a 2.3% decline in trading on September 8, 2026, following a cyberattack on August 25 that disrupted manufacturing and shipping. The company announced it is unlikely to meet its previously provided guidance for third-quarter and full-year net sales and adjusted earnings per share for 2026. While operations have resumed, the cyberattack’s effects are anticipated to impact the company's financial performance. This situation highlights operational vulnerabilities that investors might not have fully considered, creating caution regarding future earnings expectations.
Read More: Boston Scientific (BSX) Guidance Cut Due to Cyberattack Impact
Boston Scientific (BSX) Shares Fall 3.5% Due to Cyberattack
Boston Scientific (BSX) reported a cyberattack this week disrupting its operations and access to information systems, according to an SEC filing. The attack led to a 3.5% decline in premarket trading. Additionally, shares of the $72 billion medical device maker have nearly halved this year following a weak profit forecast from the first quarter. The company is working to restore affected systems, but a timeline for full restoration remains unclear, impacting investor confidence.
Read More: Boston Scientific (BSX) Shares Fall 3.5% Due to Cyberattack
Boston Scientific stock down 0.4% on market changes
Boston Scientific (BSX) shares fell by 0.4% in pre-market trading, reflecting broader market trends and trading volumes today. The decline followed announcements of upcoming financial results, which could influence investor sentiment. The stock's decline is part of a larger trend observed in the medical devices sector, where several companies are facing similar issues. For investors, this trend could indicate potential volatility and caution in future trading sessions.
Read More: Boston Scientific stock down 0.4% on market changes
Boston Scientific (BSX) reports $5.4B Q2 revenue with 7.5% growth
Boston Scientific reported Q2 revenues of $5.4 billion, reflecting a 7.5% year-over-year increase. The cardiovascular segment drove most of this revenue, generating about $3.6 billion, up 8.3% YoY. However, the company has lowered its 2026 earnings per share outlook to between $3.28 and $3.32, down from earlier expectations. Following the announcement, Boston's stock price fell by over 5% to $42.67 on July 29. This adjustment in outlook may indicate potential challenges in future growth, which is important for investors to consider.
Read More: Boston Scientific (BSX) reports $5.4B Q2 revenue with 7.5% growth
Boston Scientific (BSX) Price Target Cut to $64 by Truist
Truist has decreased its price target for Boston Scientific Corp. (BSX) from $85 to $64 while maintaining a Buy rating. This revision comes after management indicated slowing growth in the U.S. market for the Watchman device. Goldman Sachs also cut its target price for BSX from $81 to $71, while still offering a Buy rating, noting expected revenue growth of at least 7% and a double-digit increase in EPS. The adjustments reflect analysts' concerns over the product's performance but confidence in BSX's broader financial profile.
Read More: Boston Scientific (BSX) Price Target Cut to $64 by Truist
Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
Jefferies has lowered the price target for Boston Scientific (BSX) amid concerns over its growth outlook. Specific figures on the new price target or changes in revenue estimates were not disclosed in the report. This adjustment may influence investor sentiment and trading volumes as market participants evaluate the implications for BSX. Tracking the company's performance and comparing it with sector forecasts will be essential for identifying potential market movements.
Read More: Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
Boston Scientific Reports Clinical Trials Driving Growth in Cardiology Market
Boston Scientific highlighted advancements in clinical trials during the American College of Cardiology conference. The company reported a 10% year-over-year growth in its cardiovascular segment, reaching sales of $2 billion. The increased focus on innovation aims to address significant unmet clinical needs in cardiology, thereby potentially enhancing market confidence and investor interest. The expansion in clinical trials signifies a strategic move to leverage growth opportunities in a competitive healthcare landscape.
Read More: Boston Scientific Reports Clinical Trials Driving Growth in Cardiology MarketMore Health Care stocks
Frequently asked questions
Is Boston Scientific Corporation in the S&P 500?
Yes. Boston Scientific Corporation trades as BSX and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is BSX in?
BSX sits in the Health Care sector of the S&P 500.
Where can I find the latest BSX news?
Right here. This page collects recent BSX news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Boston Scientific Corporation's stock price?
BSX last traded at about $44.39. Prices move all through the session, so this is the latest quote rather than a live one.
What is Boston Scientific Corporation's market cap?
BSX is worth roughly $64.33B. Market cap is the share price times the number of shares outstanding.
What is BSX's P/E ratio?
BSX trades at a trailing P/E ratio of about 18.0. The ratio compares the share price with earnings per share over the past year.